Omnicell (NASDAQ:OMCL)‘s stock had its “overweight” rating reiterated by stock analysts at Cantor Fitzgerald in a report issued on Thursday, Marketbeat reports. They presently have a $80.00 price target on the stock, up from their prior price target of $70.00. Cantor Fitzgerald’s price objective would indicate a potential upside of 14.56% from the company’s previous close.
The analysts wrote, “. We continue to rate OMCL shares at Overweight but increase our 12-month price target to $80 from $70. We recently attended the mid- year meeting of the Pharmacists (ASHP). ASHP is the company’s most important trade show. During the show, the company hosted a small analyst event and highlighted its newest product offerings. Specifically, it appears as though the company is making good progress with its XR2 and IVX automation products. However, the key focus appears to be on software and data analytics, in order to create work flow efficiencies for hospitals and pharmacies.””
OMCL has been the subject of a number of other research reports. Wells Fargo & Co lifted their target price on shares of Omnicell from $59.00 to $61.00 and gave the company a “market perform” rating in a research note on Monday, October 29th. Craig Hallum lifted their target price on shares of Omnicell from $65.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, September 17th. BidaskClub raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Thursday, November 22nd. Zacks Investment Research raised shares of Omnicell from a “sell” rating to a “hold” rating in a research note on Monday, August 13th. Finally, Benchmark lifted their target price on shares of Omnicell from $66.00 to $79.00 and gave the company a “buy” rating in a research note on Friday, October 5th. Three analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $72.13.
Shares of NASDAQ:OMCL opened at $69.83 on Thursday. The firm has a market cap of $2.80 billion, a price-to-earnings ratio of 387.94, a P/E/G ratio of 4.22 and a beta of 0.99. Omnicell has a 12-month low of $39.75 and a 12-month high of $79.48. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.78 and a quick ratio of 1.32.
Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, October 25th. The company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.40 by $0.09. The company had revenue of $204.27 million during the quarter, compared to analyst estimates of $203.48 million. Omnicell had a net margin of 6.11% and a return on equity of 7.91%. Equities analysts forecast that Omnicell will post 1.42 EPS for the current fiscal year.
In related news, EVP Dan S. Johnston sold 6,250 shares of Omnicell stock in a transaction on Monday, October 15th. The shares were sold at an average price of $63.47, for a total value of $396,687.50. Following the completion of the sale, the executive vice president now owns 35,996 shares of the company’s stock, valued at approximately $2,284,666.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director James T. Judson sold 5,000 shares of Omnicell stock in a transaction on Monday, October 1st. The shares were sold at an average price of $71.18, for a total transaction of $355,900.00. Following the completion of the sale, the director now directly owns 29,952 shares of the company’s stock, valued at approximately $2,131,983.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 19,267 shares of company stock valued at $1,309,116. 3.71% of the stock is owned by company insiders.
Several hedge funds have recently added to or reduced their stakes in OMCL. Bank of Montreal Can acquired a new stake in shares of Omnicell in the 2nd quarter valued at $102,000. Stone Ridge Asset Management LLC acquired a new stake in shares of Omnicell in the 3rd quarter valued at $202,000. Everence Capital Management Inc. acquired a new stake in shares of Omnicell in the 3rd quarter valued at $204,000. Ibex Investors LLC acquired a new position in Omnicell during the 3rd quarter worth $209,000. Finally, Evanston Investments Inc. dba Evanston Advisors acquired a new position in Omnicell during the 3rd quarter worth $216,000.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Recommended Story: What factors cause inflation to rise?
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.